In bone tumors, the MSKCC cohort had significantly fewer mutations in MAP3K1, CREBBP, MCL1, GNAQ, MEF2B, MYCN, SDHA, and SMARCA4 (Figure 3B). The gene discussed is MYCN; the disease is bone neoplasm.